Altimmune (ALT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ALT Altimmune

Watchlist

6.290
+0.150+2.44%

Close Oct 1 16:00 ET

6.270
-0.020-0.32%

Post 19:13 ET

447.04MMarket Cap-3858P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Seeking AlphaOct 1 10:22 ET
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
GlobeNewswireOct 1 07:30 ET
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Seeking AlphaSep 30 11:25 ET
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
InvestingSep 30 07:36 ET
Express News | Altimmune: To File Ind Applications for Pemvidutide in up to 3 Additional Indications With First of These Ind Submissions in Q4
ReutersSep 30 07:30 ET
Express News | Altimmune Inc - End-of-Phase 2 Meeting With FDA Scheduled for November 2024
ReutersSep 30 07:30 ET

Comments

Clembot82

Yesterday 01:54

Wish I had some dry powder

$Altimmune (ALT.US)$ Money tied up on some other plays, well see how long is at these levels. There are always more opportunities to come. 🐂 📈

frogoracletrading

Sep 21 12:45

$ALT Support / Resistance Levels

Watching for consolidation over the 7.40 top of the POC to setup a push to 10.00+
Larger Image: tradingview.com...
$Altimmune (ALT.US)$

Trytosaveabit

Sep 10 06:56

Update

$Altimmune (ALT.US)$ Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity
Benzinga· 1 min ago
In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was 21.9%.
Lean mass preservation was greater in subjects aged 60 years and older, in whom the ...

Jaguar8

Sep 10 06:46

NEWS

$Altimmune (ALT.US)$
Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes
Altimmune presented results from a Phase 2 MRI-based body composition sub-study of pemvidutide at the 60th Annual Meeting of the European Association for the Study of Diabetes. The study, involving 67 subjects from the MOMENTUM obesity trial, showed promising outcomes for pemvidutide, a novel GLP-1/glucagon dual receptor...